Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
51146-56-6
Molecular formula
C13H18O2
Molecular weight
206.28 g/mol
Drug class
Non-steroidal anti-inflammatory drug (NSAID)pharmacologically active S(+)-enantiomer of ibuprofen
Mechanism of action
A non-selective cyclo-oxygenase inhibitor that reduces prostaglandin synthesis, producing analgesic, anti-inflammatory and antipyretic effects; it also inhibits platelet aggregation.
Indications / reported uses
Symptomatic treatment of pain and inflammation in osteoarthritis
Primary dysmenorrhoea
Mild-to-moderate pain, including musculoskeletal pain, headache and toothache
Short-term symptomatic treatment of rheumatoid arthritis when disease-modifying therapy is not being considered; the cited UK SmPC includes adults and children/adolescents from 8 years
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Dexibuprofen Environmental Risk Assessment (ERA) (the Dexibuprofen ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.